002349 精华制药
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入379,7644.46%1,459,9571,402,0881,511,7511,573,060
减:营业总成本283,3811.47%1,161,3191,110,1571,185,1971,333,249
    其中:营业成本169,416-3.26%702,400705,569775,642837,915
               财务费用(3,176)-33.13%(23,393)(44,749)(23,146)(15,046)
               资产减值损失(3,634)-3.78%(10,754)(15,258)(7,949)(23,187)
公允价值变动收益1,31568.10%4,1743,8166,8324,991
投资收益71150.72%3,5724,37223824,465
    其中:对联营企业和合营企业的投资收益------(661)(1,256)--
营业利润94,06813.68%304,286295,058330,854251,484
利润总额94,49413.15%303,606293,318329,695250,213
减:所得税费用12,7446.27%41,77045,85253,22937,924
净利润81,75014.31%261,836247,466276,467212,289
减:非控股权益15,87770.76%42,55134,81528,76964
股东净利润65,8735.87%219,285212,652247,697212,225

市场价值指针
每股收益 (元) *0.0815.89%0.2680.2610.3040.261
每股派息 (元) *----0.0900.0790.0920.080
每股净资产 (元) *3.4044.70%3.3183.1733.0032.949
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容